Nakagomi Osamu, Nakagomi Toyoko
Division of Molecular Epidemiology, Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University.
Uirusu. 2010 Jun;60(1):33-48. doi: 10.2222/jsv.60.33.
Rotavirus is the most important cause of severe gastroenteritis in children worldwide, and is most effectively controlled by vaccines. The Strategic Advisory Group of Experts (SAGE) of the World Health Organization (WHO) recommended, in 2009, the inclusion of rotavirus vaccination of infants into all national immunization programs. Two, live, orally-administrable vaccines are licensed globally. They are Rotarix, a G1P[8] monovalent, human rotavirus-based vaccine (GlaxoSmithKline), and RotaTeq, a pentavalent, bovine-human reassortant vaccine (Merck). Although the two vaccines are very different in antigenic composition and administration schedule, they are almost equally safe with respect to intussusception and 90-100% efficacious against severe rotavirus diarrhea. Countries where either vaccine was introduced into the national childhood immunization program have witnessed not only a drastic decrease in the number of rotavirus hospitalizations but a near 50% reduction in the number of all-cause-diarrhea hospitalizations. Rotavirus diarrhea, an emerging infectious disease because of its discovery in 1973, may now be among vaccine preventable diseases.
轮状病毒是全球儿童严重肠胃炎的最重要病因,而疫苗是控制该病毒的最有效手段。2009年,世界卫生组织(WHO)的战略咨询专家组(SAGE)建议将婴儿轮状病毒疫苗纳入所有国家免疫规划。全球有两种口服的活疫苗获得许可。一种是Rotarix,一种基于人G1P[8]型轮状病毒的单价疫苗(葛兰素史克公司);另一种是RotaTeq,一种五价牛-人重配疫苗(默克公司)。尽管这两种疫苗在抗原组成和接种程序上有很大差异,但在肠套叠方面安全性几乎相同,对重症轮状病毒腹泻的预防效力达90%至100%。将任何一种疫苗纳入国家儿童免疫规划的国家不仅见证了轮状病毒住院病例数的大幅下降,还见证了所有病因导致的腹泻住院病例数近乎50%的减少。轮状病毒腹泻是一种1973年才被发现的新发传染病,如今可能属于可通过疫苗预防的疾病。